For example, in the treatment of Alzheimers diseases (AD) and Parkinsons diseases (PD), GLP-1RAs have shown potential in slowing disease progression, while their anti-inflammatory properties offer new hope for conditions such as osteoarthritis (OA), rheumatoid arthritis (RA) and cardiovascular diseases.13,14,15 By integrating the latest clinical trial data, we explore the efficacy of GLP-1RAs in treating diseases of the nervous, cardiovascular, endocrine, and digestive systems
The authorised product has a defined formulation, manufacturing controls, dosing schedule, administration setting, adverse-event monitoring, label, and patient population
They can help with weight loss by making you less hungry
Evidence Summary There is currently insufficient evidence of consistent magnesium depletion directly caused by GLP-1 therapy